SCHEMBL738735

SCHEMBL738735

CCOC(=O)n1nc(NC(=O)c2cccs2)c2cc(C(=O)NC(C)(C)c3ccccc3)sc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.43
L3MBTL1 Q9Y468 7/20 0.43
MAPK1 P28482 7/20 0.43
TDP1 Q9NUW8 6/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 7/20 0.42
HPGD P15428 7/20 0.42
MAPT P10636 7/20 0.42
GLA P06280 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 6/20 0.41
HSD17B10 Q99714 6/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
CASP1 P29466 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 3/20 0.41
TSHR P16473 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741012 0.86 KDM4E (0.47) KDM4EL3MBTL1MAPK1TDP1KMT2A
SCHEMBL1780180 0.86 KDM4E (0.38) KDM4EMAPK1KMT2AMEN1ALDH1A1
SCHEMBL4633164 0.86 ABL1 (0.44) KDM4EMAPK1KMT2AMEN1LMNA
SCHEMBL742599 0.85 KDM4E (0.46) KDM4EL3MBTL1MAPK1TDP1KMT2A
SCHEMBL740838 0.85 KDM4E (0.42) KDM4EL3MBTL1MAPK1TDP1KMT2A
SCHEMBL740983 0.85 AURKA (0.39) KDM4EMAPK1KMT2AMEN1ALDH1A1
SCHEMBL741094 0.84 ABL1 (0.48) KDM4EKMT2AMEN1LMNAALDH1A1
SCHEMBL12603552 0.84 KDM4E (0.37) KDM4EMAPK1KMT2AMEN1ALDH1A1
SCHEMBL1779446 0.84 ALDH1A1 (0.43) KDM4EL3MBTL1KMT2AMEN1LMNA
SCHEMBL6441461 0.83 ALDH1A1 (0.43) KDM4EL3MBTL1MAPK1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481584-B2 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-07-09 US disclosed
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-28 US disclosed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed
EP-1711177-B1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K3 KDM4E 1435/4885L3MBTL1 2956/4885MAPK1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.